EB-104

N/A

Report date: 2025/01/26 16:27:24

Base Information

Drug NameEB-104

Drug Alias Namedual anti-CD19/CD22 TCR T cell therapy (Estrella Biopharma)EB-104

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionCD22 modulatorsB-lymphocyte antigen CD19 modulators

TargetsCD22B-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEstrella Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesEstrella Immunopharma Inc

Inactive CompaniesEstrella Biopharma Inc

Active IndicationsLymphoma, Large B-Cell, DiffusePrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A